Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

This is a multicenter, randomized, double-blind, placebo-controlled study to assess whether trilaciclib administered prior to topotecan is non-inferior to placebo administered prior to topotecan with regard to overall survival.

Trial Details

NCT ID
NCT05874401
Phase
PHASE4
Sponsor
Pharmacosmos A/S
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Trilaciclib
  • Placebo
  • Topotecan
Locations (sample)
  • Seville, Spain|37.38283,-5.97317

Key Eligibility Criteria

  • ES-SCLC with confirmed diagnosis of SCLC by histology or cytology
  • Progression during or after prior first or second line chemotherapy. First-line regimen must have been a platinum-containing combination.
  • Measurable or evaluable disease as defined by RECIST v1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →